GlassScriptPhysician profile
Nathaniel Wachter
NPI 1922492123
$27,372.00
in general payments reported to CMS, 2019-2025
42 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20K · 2021: $123 · 2022: $1,010 · 2023: $1,600 · 2024: $3,280 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,163 · Education: $10.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,162.58 |
| Education | $10.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $15,000.00 | 2020 | |
| Boston Scientific Corporation | $5,129.51 | 2020-2022 | |
| Abbvie INC. | $2,690.61 | 2022-2025 | Botox, Ubrelvy, Duopa |
| Supernus Pharmaceuticals, INC. | $669.37 | 2022-2024 | Qelbree |
| Medtronic, INC. | $557.65 | 2021-2025 | Percept PC Brainsense, Activa PC, Sensight |
| Lilly USA, LLC | $402.71 | 2022-2025 | Emgality, Kisunla, Amyvid |
| Ucb, INC. | $392.77 | 2023-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Biogen, INC. | $280.94 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Mdd US Operations, LLC | $257.30 | 2023-2024 | Apokyn, Apokyn, Gocovri |
| Pfizer INC. | $173.27 | 2023-2025 | |
| Lundbeck LLC | $165.41 | 2020-2024 | Vyepti |
| Novartis Pharmaceuticals Corporation | $148.93 | 2024-2025 | |
| Neurelis, INC. | $145.58 | 2023-2025 | Valtoco |
| Emd Serono, INC. | $115.85 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $104.02 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $96.38 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $92.01 | 2023-2024 | Aptiom |
| Neurocrine Biosciences, INC. | $81.34 | 2024-2025 | Ingrezza |
| Catalyst Pharmaceuticals, INC. | $73.04 | 2023-2024 | Fycompa |
| Grifols USA, LLC | $65.58 | 2024-2025 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $65.57 | 2023-2025 | Crexont, Rytary |
| Xeris Pharmaceuticals, INC. | $60.45 | 2024-2025 | Keveyis |
| Allergan, INC. | $57.12 | 2021-2022 | |
| Amgen INC. | $53.95 | 2022-2023 | Aimovig |
| Alexion Pharmaceuticals, INC. | $48.76 | 2023-2024 | Ultomiris |
| Tg Therapeutics, INC. | $47.74 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $42.38 | 2024 | Wainua |
| Acorda Therapeutics, INC | $40.33 | 2023-2024 | Inbrija, Ampyra |
| Jazz Pharmaceuticals INC. | $34.07 | 2024 | |
| Genentech USA, INC. | $33.11 | 2023 | Ocrevus |
| Csl Behring | $32.15 | 2023 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $30.31 | 2024 | Hyqvia |
| Genzyme Corporation | $28.41 | 2024 | |
| Sk Life Science, INC. | $26.40 | 2025 | |
| Axsome Therapeutics, INC. | $25.23 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $17.95 | 2024 | Nuplazid |
| Impel Pharmaceuticals INC. | $17.10 | 2023 | Trudhesa |
| Averitas Pharma INC. | $16.89 | 2023 | Qutenza |
| Kyowa Kirin, INC. | $13.84 | 2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $13.03 | 2022 | |
| Currax Pharmaceuticals LLC | $12.83 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Wachter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.